# Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity

> **NCT01849640** · NA · SUSPENDED · sponsor: **David Saunders** · enrollment: 150 (estimated)

## Conditions studied

- Uncomplicated Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** DHA-piperaquine and Primaquine

## Key facts

- **NCT ID:** NCT01849640
- **Lead sponsor:** David Saunders
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-12
- **Primary completion:** 2014-12
- **Final completion:** 2016-06
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Poor efficacy of DHA-piperaquine due to likely drug resistance.
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849640, "Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01849640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*